Literature DB >> 15506237

Fatty acid profile and affective dysregulation in irritable bowel syndrome.

Tessa O C Kilkens1, Adriaan Honig, Michael Maes, Richel Lousberg, Robert-Jan M Brummer.   

Abstract

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder with a high co-occurrence with affective dysregulation. Affective disorders have been associated with specific changes in the PUFA and cholesterol profile. In IBS, similar changes may be present as have been reported in patients with affective disorders. This exploratory study investigates (i) the level of affective dysregulation (AD) in IBS patients and healthy controls; (ii) PUFA and cholesterol profiles in IBS patients compared with controls; and (iii) associations between PUFA and cholesterol parameters with the level of AD. Blood samples were obtained for determination of the FA composition of plasma phospholipids and serum cholesterol in 23 diarrhea-predominant IBS patients and 23 healthy matched controls. AD was scored using the Symptom Check List depression scale, the Hospital Anxiety and Depression Scale, and the Hamilton Depression Rating Scale. The level of AD was higher in IBS patients compared with controls. PUFA and cholesterol profiles did not differ significantly between groups. Total n-3 PUFA and cholesterol were significantly negatively associated and the ratio of n-6 to n-3 PUFA and the ratio of arachidonic acid to EPA were significantly positively associated with the level of AD. The findings of the present study reveal that AD was higher in IBS patients compared with healthy controls and that changes in PUFA and cholesterol profiles were significantly associated with the level of AD. These results warrant further studies regarding the role of PUFA and cholesterol status in the co-occurrence of AD and functional gastrointestinal disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15506237     DOI: 10.1007/s11745-004-1247-x

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  54 in total

1.  Eicosapentaenoic acid in treatment-resistant depression.

Authors:  Basant K Puri; Serena J Counsell; Alexandra J Richardson; David F Horrobin
Journal:  Arch Gen Psychiatry       Date:  2002-01

Review 2.  Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes.

Authors:  D F Horrobin; C N Bennett
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1999-04       Impact factor: 4.006

3.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

4.  The burden of selected digestive diseases in the United States.

Authors:  Robert S Sandler; James E Everhart; Mark Donowitz; Elizabeth Adams; Kelly Cronin; Clifford Goodman; Eric Gemmen; Shefali Shah; Aida Avdic; Robert Rubin
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

Review 5.  Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy.

Authors:  J R Hibbeln; N Salem
Journal:  Am J Clin Nutr       Date:  1995-07       Impact factor: 7.045

Review 6.  Irritable bowel syndrome: a little understood organic bowel disease?

Authors:  Nicholas J Talley; Robin Spiller
Journal:  Lancet       Date:  2002-08-17       Impact factor: 79.321

Review 7.  Overview of functional gastrointestinal disorders: dysfunction of the brain-gut axis.

Authors:  Howard R Mertz
Journal:  Gastroenterol Clin North Am       Date:  2003-06       Impact factor: 3.806

8.  Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects.

Authors:  A Prior; D G Maxton; P J Whorwell
Journal:  Gut       Date:  1990-04       Impact factor: 23.059

Review 9.  A role for inflammation in irritable bowel syndrome?

Authors:  G Barbara; R De Giorgio; V Stanghellini; C Cremon; R Corinaldesi
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 10.  Systematic review: serotonergic modulators in the treatment of irritable bowel syndrome--influence on psychiatric and gastrointestinal symptoms.

Authors:  T O C Kilkens; A Honig; N Rozendaal; M A Van Nieuwenhoven; R-J M Brummer
Journal:  Aliment Pharmacol Ther       Date:  2003-01       Impact factor: 8.171

View more
  5 in total

1.  Marked elevations in pro-inflammatory polyunsaturated fatty acid metabolites in females with irritable bowel syndrome.

Authors:  Gerard Clarke; Peter Fitzgerald; Alan A Hennessy; Eugene M Cassidy; Eamonn M M Quigley; Paul Ross; Catherine Stanton; John F Cryan; Timothy G Dinan
Journal:  J Lipid Res       Date:  2009-11-11       Impact factor: 5.922

Review 2.  Homeostasis of the gut barrier and potential biomarkers.

Authors:  Jerry M Wells; Robert J Brummer; Muriel Derrien; Thomas T MacDonald; Freddy Troost; Patrice D Cani; Vassilia Theodorou; Jan Dekker; Agnes Méheust; Willem M de Vos; Annick Mercenier; Arjen Nauta; Clara L Garcia-Rodenas
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-12-01       Impact factor: 4.052

3.  Depressive symptoms in patients with irritable bowel syndrome: a meta-analysis of comparative studies.

Authors:  Qing-E Zhang; Fei Wang; Geng Qin; Wei Zheng; Chee H Ng; Gabor S Ungvari; Zhen Yuan; Songli Mei; Gang Wang; Yu-Tao Xiang
Journal:  Int J Biol Sci       Date:  2018-08-15       Impact factor: 6.580

4.  Fatty acid components in Asian female patients with irritable bowel syndrome.

Authors:  Chian Sem Chua; Shih-Yi Huang; Chiao-Wen Cheng; Chyi-Huey Bai; Chien-Yeh Hsu; Hung-Wen Chiu; Jung-Lung Hsu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

5.  Dietary Habits and Abdominal Pain-related Functional Gastrointestinal Disorders: A School-based, Cross-sectional Analysis in Greek Children and Adolescents.

Authors:  Giorgos Chouliaras; Christina Kondyli; Ilias Bouzios; Nick Spyropoulos; George P Chrousos; Eleftheria Roma-Giannikou
Journal:  J Neurogastroenterol Motil       Date:  2019-01-31       Impact factor: 4.924

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.